An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia
| Status: | Archived |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | September 2009 |
| End Date: | December 2010 |
An Observational Registration Study of Infusion-related Adverse Events at Administration of Mabthera (Rituximab) in the Treatment of Chronic Lymphocytic Leukemia.
This observational study will monitor and register infusion-related adverse events and their
handling in patients with chronic lymphocytic leukemia on treatment with MabThera
(rituximab). Data will be collected from patients receiving intravenous MabThera at a dose
of 375mg/m2 in cycle 1 and 500mg/m2 in subsequent cycles at each treatment visit for up to 6
months. Target sample size is 100 patients.
We found this trial at
1
site
Click here to add this to my saved trials
